RhIMAB Study
Enrolling By Invitation
18 years - 99 years
All
Phase
N/A
720 participants needed
1 Location
Brief description of study
Participation in this research study is presented as a voluntary option to those women presenting at Penn Medicine and choosing medication abortion.
The research team seeks to asses the value of blood typing and the provision of Rh immune globulin to women choosing medication abortion at 10 weeks and 0 days or less.
We will measure the degree of feto-maternal hemorrhage experienced in medication abortion patients up to 10 weeks gestation, and determine at which gestational ages, if any, Rh immune globulin prophylaxis is indicated for this population.
Participation will last until the survey that will occur 30 days after Visit 1
.There is no expected benefit from being in this research study. Anticipated future benefits include a better understanding of the need for Rh immune globulin for those seeking medication abortion.
The most common risks of participation are those associated with the blood draw, including pain, dizziness or fainting, bruising, or infection at the needle insertion site. It is unlikely that removing this small amount of blood will result in symptoms.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: abortion,Rh,hemorrhage,pregnancy
-
Age: 18 years - 99 years
-
Gender: All
Inclusion criteria: Gestational age up to 10 weeks 0 days, seeking medication abortion.
Exclusion criteria: Homozygous for sickle cell disease, thalassemia, hemoglobinopathies, or hereditary persistence of fetal hemoglobin by self-report, inability to consent, currently taking anticoagulants, unwillingness to adhere to the protocol
Updated on
04 Aug 2024.
Study ID: 832611
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
